InflaRx to Present at Upcoming Investor Conferences
March 03 2021 - 7:30AM
InflaRx N.V. (Nasdaq: IFRX), a clinical-stage
biopharmaceutical company developing anti-inflammatory therapeutics
by targeting the complement system, today announced that management
will present at two upcoming virtual investor conferences.
H.C. Wainwright Global Life Sciences
ConferenceMarch 9-10, 2021An on-demand
corporate presentation from Prof. Niels C. Riedemann, Chief
Executive Officer and Founder of InflaRx, will be available
starting at 7:00 am EST (1:00 pm CET) on March 9, 2021. A webcast
of the event will be accessible on the InflaRx website in the
Investors section under Events & Presentations.
Oppenheimer
31st Annual Healthcare
ConferenceTuesday, March 16, 2021 at 8:00 am EST
(1:00 pm CET)A live webcasted corporate presentation
from Prof. Riedemann will be available on the InflaRx website in
the Investors section under Events & Presentations. A replay of
the presentation will be accessible on InflaRx’s website following
the live event.
About InflaRx N.V.: InflaRx
(Nasdaq: IFRX) is a clinical-stage biopharmaceutical company
focused on applying its proprietary anti-C5a technology to discover
and develop first-in-class, potent and specific inhibitors of C5a.
Complement C5a is a powerful inflammatory mediator involved in the
progression of a wide variety of autoimmune and other inflammatory
diseases. InflaRx was founded in 2007, and the group has offices
and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor,
MI, USA. For further information please visit www.inflarx.com.
Contacts:
InflaRx N.V.Jordan Zwick –
Chief Strategy OfficerEmail: IR@inflarx.deTel: +1 917-338-6523
MC Services AGKatja Arnold,
Laurie Doyle, Andreas JungferEmail: inflarx@mc-services.euEurope:
+49 89-210 2280US: +1-339-832-0752
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking
statements. All statements other than statements of historical fact
are forward-looking statements, which are often indicated by terms
such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,”
“could,” “intend,” “target,” “project,” “believe,” “estimate,”
“predict,” “potential” or “continue” and similar expressions.
Forward-looking statements appear in a number of places throughout
this release and may include statements regarding our intentions,
beliefs, projections, outlook, analyses and current expectations
concerning, among other things, our ongoing and planned preclinical
development and clinical trials; the impact of the COVID-19
pandemic on the Company; the timing and our ability to commence and
conduct clinical trials; potential results from current or
potential future collaborations; our ability to make regulatory
filings, obtain positive guidance from regulators, and obtain and
maintain regulatory approvals for our product candidates; our
intellectual property position; our ability to develop commercial
functions; expectations regarding clinical trial data; our results
of operations, cash needs, financial condition, liquidity,
prospects, future transactions, growth and strategies; the industry
in which we operate; the trends that may affect the industry or us
and the risks uncertainties and other factors described under the
heading “Risk Factors” in InflaRx’s periodic filings with the
Securities and Exchange Commission. These statements speak only as
of the date of this press release and involve known and unknown
risks, uncertainties and other important factors that may cause our
actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements. Given these
risks, uncertainties and other factors, you should not place undue
reliance on these forward-looking statements, and we assume no
obligation to update these forward-looking statements, even if new
information becomes available in the future, except as required by
law.
InflaRx NV (NASDAQ:IFRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
InflaRx NV (NASDAQ:IFRX)
Historical Stock Chart
From Apr 2023 to Apr 2024